Search

Your search keyword '"González-Merino C"' showing total 11 results
Start Over Author "González-Merino C"
11 results on '"González-Merino C"'

3. 1936P Treatment outcomes of patients with anaplastic thyroid carcinoma (atc): Multicentric data from spanish national registry (regetne-tiroides)

Author

Rodellar, J.M., Hernando Cubero, J., Garcia Alvarez, A., Ceballos Lenza, I., Plana Serrahima, M., Gallardo, E., Bella, M.R., Jimenez Fonseca, P., Lopez, C., Jimeno Mate, R., Martinez Lago, N., Ayala de Miguel, P., Molina Cerrillo, J., Granados, A.R., Gonzalez Merino, C., Viana Aragonés, M., González Martín, G., Capdevila Castillon, J., and Alonso Gordoa, T.

Published
2024
Full Text
View/download PDF

4. 1849P Clinical predictors of long-term responses to immune checkpoint inhibitors (ICI) in a multi-tumor cohort

Author

Albarrán Fernández, V., Guerrero, P., Gonzalez Merino, C., García de Quevedo Suero, C., Chamorro-Perez, J., Rosero Rodriguez, D.I., Barrill Corpa, A.M., Sotoca-Rubio, P., Alia Navarro, V., Pérez de Aguado, P., Calvo, J.C., Moreno, J., San Roman Gil, M.V., Alvarez Ballesteros, P., Cortes Salgado, A., Olmedo Garcia, M.E., Gomez Rueda, A., Garrido Lopez, P., Soria Rivas, A., and Gajate, P.

Published
2024
Full Text
View/download PDF

6. 1063P Influence of infusion timing on the outcomes of immunotherapy in a multi-tumor cohort

Author

Albarrán Fernández, V., Rosero Rodriguez, D.I., Chamorro-Perez, J., Guerrero, P., Gonzalez Merino, C., García de Quevedo Suero, C., Sotoca-Rubio, P., Barrill Corpa, A.M., Alia Navarro, V., Moreno, J., Calvo, J.C., Pérez de Aguado, P., San Roman Gil, M.V., Alvarez Ballesteros, P., Saavedra Serrano, C., Soria Rivas, A., Olmedo Garcia, M.E., Garrido Lopez, P., Cortes Salgado, A., and Gajate, P.

Published
2024
Full Text
View/download PDF

7. 2224P Identifying prognostic factors in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) treated with tyrosine kinase inhibitors (TKI): Data from REGETNE registry

Author

San Roman Gil, M.V., Hernando, J., Granados, A.R., Carmona, A., Marquina Ospina, G., Bella, M.R., Castelo, B., Campos Ramirez, S.E., Molina Cerrillo, J., Ruz-Caracuel, I., Valderrabano, P., Luengo Pierrard, P., Roca Herrera, M., Garcia Alvarez, A., Pozas Perez, J., Gonzalez Merino, C., Alonso Gordoa, T., and Capdevila Castillon, J.

Published
2023
Full Text
View/download PDF

8. 1066P Negative impact of steroids on the efficacy of immunotherapy in a multi-tumor cohort of patients: time and dose-dependent

Author

Albarrán, V., Guerrero, P., Gonzalez Merino, C., García de Quevedo, C., Barrill Corpa, A.M., Sotoca-Rubio, P., Alia Navarro, V., Pérez de Aguado, P., Calvo, J.C., Moreno, J., Chamorro-Perez, J., Rosero Rodriguez, D.I., Alvarez Ballesteros, P., Serrano, J.J., Saavedra Serrano, C., Ruiz, Á., Gomez Rueda, A., Soria Rivas, A., Garrido Lopez, P., and Gajate Borau, P.

Published
2023
Full Text
View/download PDF

9. Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients.

Author

Guerrero P, Albarrán V, González-Merino C, García de Quevedo C, Sotoca P, Chamorro J, Rosero DI, Barrill A, Alía V, Calvo JC, Moreno J, Pérez de Aguado P, Álvarez-Ballesteros P, San Román M, Serrano JJ, Soria A, Olmedo ME, Saavedra C, Cortés A, Gómez A, Lage Y, Ruiz Á, Ferreiro MR, Longo F, Guerra E, Martínez-Delfrade Í, Garrido P, and Gajate P

Abstract

Background: Immune checkpoint inhibitors (ICI) have changed the therapeutic landscape of many solid tumors. Modulation of the intestinal microbiota by antibiotics (Abx) has been suggested to impact on ICI outcomes., Methods: Retrospective analysis of 475 patients with advanced solid tumors treated with ICI from 2015 to 2022. For each patient, the use of Abx was recorded from 1 month before ICI initiation until disease progression or death. The impact of Abx on objective response rates (ORR), disease control rates (DCR), progression-free survival (PFS), and overall survival (OS) was analyzed. Kaplan-Meier and log-rank tests were used to compare survival outcomes., Results: In total 475 patients with advanced solid tumors were evaluated. Median age was 67.5 years and performance status (PS) was 0-1 in 84.6%. 66.5% of patients received Abx during treatment with ICI, mainly beta-lactams (53.8%) and quinolones (35.9%). The early exposure to Abx (from 60 days before to 42 days after the first cycle of ICI) was associated with a lower ORR (27.4% vs 39.4%; P < .01), a lower DCR (37.3% vs 57.4%; P < .001), lower PFS (16.8 m vs 27.8 m; HR 0.66; P < .001]) and lower OS (2.5 m vs 6.6 m; HR 0.68; P = .001]). The negative impact of Abx on OS and PFS was confirmed by a multivariable analysis. This effect was not observed among patients receiving Abx after 6 weeks from ICI initiation., Conclusions: Our results validate the hypothesis of a detrimental effect of an early exposure to Abxon the efficacy of ICI in a multi-tumor cohort of patients., (© The Author(s) 2024. Published by Oxford University Press.)

Published
2024
Full Text
View/download PDF

10. Case report: Efficacy of immunotherapy as conversion therapy in dMMR/MSI-H colorectal cancer: a case series and review of the literature.

Author

San-Román-Gil M, Martínez-Delfrade I, Albarrán-Fernández V, Guerrero-Serrano P, Pozas-Pérez J, Chamorro-Pérez J, Rosero-Rodríguez D, Sotoca-Rubio P, Barrill-Corpa AM, Alia-Navarro V, González-Merino C, García-de-Quevedo-Suero C, López V, Ruz-Caracuel I, Perna-Monroy C, and Ferreiro-Monteagudo R

Subjects
Humans, Immunotherapy, Research, Neoadjuvant Therapy, Microsatellite Instability, Colorectal Neoplasms genetics, Colorectal Neoplasms therapy
Abstract

Immunotherapy has demonstrated a role in the therapeutic landscape of a small subset of patients with colorectal carcinoma (CRC) that harbor a microsatellite instability (MSI-H) status due to a deficient DNA mismatch repair (dMMR) system. The remarkable responses to immune checkpoint inhibitors (ICIs) are now being tested in the neoadjuvant setting in localized CRC, where the dMMR/MSI-H status can be found in up to 15% of patients, with remarkable results obtained in NICHE2 and 3 trials, among others. This case series aims to report our experience at a tertiary center and provide a comprehensive analysis of the possible questions and challenges to overcome if ICIs were established as standard of care in a neoadjuvant setting, as well as the potential role they may have as conversion therapy not only in locoregional advanced CRC but also in oligometastatic disease., Competing Interests: RF-M declares the following conflicts of interest—Advisory: Servier, Amgen, Pierre Fabre, Merck Sharp & Dohme (MSD); Speaker: Servier, Amgem, Merck, Pierre Fabre; Travels and other honoraria: Sanofi, Merck, Servier, Amgen. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 San-Román-Gil, Martínez-Delfrade, Albarrán-Fernández, Guerrero-Serrano, Pozas-Pérez, Chamorro-Pérez, Rosero-Rodríguez, Sotoca-Rubio, Barrill-Corpa, Alia-Navarro, González-Merino, García-de-Quevedo-Suero, López, Ruz-Caracuel, Perna-Monroy and Ferreiro-Monteagudo.)

Published
2024
Full Text
View/download PDF

11. BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature.

Author

Guerrero P, Albarrán V, San Román M, González-Merino C, García de Quevedo C, Moreno J, Calvo JC, González G, Orejana I, Chamorro J, Martínez-Delfrade Í, Morón B, de Frutos B, and Ferreiro MR

Abstract

Metastatic colorectal cancer (mCRC) with mutated BRAF exhibits distinct biological and molecular features that set it apart from other subtypes of CRC. Current standard treatment for these tumors involves a combination of chemotherapy (CT) and VEGF inhibitors. Recently, targeted therapy against BRAF and immunotherapy (IT) for cases with microsatellite instability (MSI) have been integrated into clinical practice. While targeted therapy has shown promising results, resistance to treatment eventually develops in a significant portion of responsive patients. This article aims to review the available literature on mechanisms of resistance to BRAF inhibitors (BRAFis) and potential therapeutic strategies to overcome them.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results